FY2025 EPS Estimates for REGN Raised by Cantor Fitzgerald

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for Regeneron Pharmaceuticals in a research note issued to investors on Wednesday, April 30th. Cantor Fitzgerald analyst C. Gould now expects that the biopharmaceutical company will earn $26.88 per share for the year, up from their prior forecast of $26.38. Cantor Fitzgerald currently has a “Overweight” rating and a $695.00 target price on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the prior year, the business posted $9.55 EPS. The firm’s quarterly revenue was down 3.7% compared to the same quarter last year.

Several other equities research analysts have also commented on the company. Royal Bank of Canada cut their price objective on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an “outperform” rating for the company in a research note on Wednesday. Bank of America dropped their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research note on Thursday, April 17th. BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $865.00 to $800.00 and set an “outperform” rating on the stock in a research note on Wednesday. Truist Financial cut their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Sanford C. Bernstein lowered their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, eighteen have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $892.60.

Regeneron Pharmaceuticals Stock Down 1.5 %

Regeneron Pharmaceuticals stock opened at $590.00 on Thursday. Regeneron Pharmaceuticals has a 12 month low of $525.99 and a 12 month high of $1,211.20. The stock has a market capitalization of $64.50 billion, a PE ratio of 15.41, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The business has a 50 day simple moving average of $628.85 and a 200-day simple moving average of $714.29.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Capital International Investors increased its position in Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after buying an additional 1,390,534 shares during the period. Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $802,036,000. GAMMA Investing LLC increased its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after acquiring an additional 814,713 shares during the period. Price T Rowe Associates Inc. MD raised its position in Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock valued at $1,485,527,000 after purchasing an additional 810,144 shares during the last quarter. Finally, Amundi boosted its stake in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.